Shanghai Yake Biotechnology Co., Ltd. has the top international immunotherapy technique (CAR-T) team.

Yake Biology has gathered a batch of senior returned doctors, masters and cell culture experts, and has more than 20 R&D pipelines for CAR-T cell products, 8 of which for treatment of blood tumors have entered clinical research by the end of 2018. In the clinical research of blood tumor in China, Yake has cooperated with those professional hospitals, and treated more than 800 cases with the complete remission rate (CR) of more than 90%, while it has reached the treatment effect of leading national and international advanced level.


http://www.yakebiotech.net/